1053 related articles for article (PubMed ID: 12154405)
21. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
Murao K; Kubo Y; Ohtani N; Hara E; Arase S
Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
[TBL] [Abstract][Full Text] [Related]
22. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.
Robert MF; Morin S; Beaulieu N; Gauthier F; Chute IC; Barsalou A; MacLeod AR
Nat Genet; 2003 Jan; 33(1):61-5. PubMed ID: 12496760
[TBL] [Abstract][Full Text] [Related]
23. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer.
Belshaw NJ; Elliott GO; Williams EA; Bradburn DM; Mills SJ; Mathers JC; Johnson IT
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1495-501. PubMed ID: 15342451
[TBL] [Abstract][Full Text] [Related]
24. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas.
Oue N; Motoshita J; Yokozaki H; Hayashi K; Tahara E; Taniyama K; Matsusaki K; Yasui W
J Pathol; 2002 Sep; 198(1):55-9. PubMed ID: 12210063
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.
Galm O; Wilop S; Lüders C; Jost E; Gehbauer G; Herman JG; Osieka R
Ann Hematol; 2005 Dec; 84 Suppl 1():39-46. PubMed ID: 16231140
[TBL] [Abstract][Full Text] [Related]
26. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells.
Song JZ; Stirzaker C; Harrison J; Melki JR; Clark SJ
Oncogene; 2002 Feb; 21(7):1048-61. PubMed ID: 11850822
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
28. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma.
Hamilton DW; Lusher ME; Lindsey JC; Ellison DW; Clifford SC
Cancer Lett; 2005 Sep; 227(1):75-81. PubMed ID: 16051033
[TBL] [Abstract][Full Text] [Related]
30. DNA hypermethylation: when tumour suppressor genes go silent.
Garinis GA; Patrinos GP; Spanakis NE; Menounos PG
Hum Genet; 2002 Aug; 111(2):115-27. PubMed ID: 12189484
[TBL] [Abstract][Full Text] [Related]
31. [The roles of DNA methylation in human neoplasms].
Yuan YF; Li JQ; Yang ZL; Wang JP
Ai Zheng; 2002 Nov; 21(11):1267-77. PubMed ID: 12526230
[TBL] [Abstract][Full Text] [Related]
32. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma.
Furonaka O; Takeshima Y; Awaya H; Ishida H; Kohno N; Inai K
Pathol Int; 2004 Aug; 54(8):549-55. PubMed ID: 15260845
[TBL] [Abstract][Full Text] [Related]
33. Hypermethylation of gene promoters in hematological neoplasia.
Chim CS; Liang R; Kwong YL
Hematol Oncol; 2002 Dec; 20(4):167-76. PubMed ID: 12469326
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation and gene silencing in cancer: which is the guilty party?
Clark SJ; Melki J
Oncogene; 2002 Aug; 21(35):5380-7. PubMed ID: 12154400
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
36. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.
Lusher ME; Lindsey JC; Latif F; Pearson AD; Ellison DW; Clifford SC
Cancer Res; 2002 Oct; 62(20):5906-11. PubMed ID: 12384556
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
[TBL] [Abstract][Full Text] [Related]
38. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
[TBL] [Abstract][Full Text] [Related]
39. CpG island methylator phenotypes in aging and cancer.
Toyota M; Issa JP
Semin Cancer Biol; 1999 Oct; 9(5):349-57. PubMed ID: 10547343
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes.
Shiraishi M; Sekiguchi A; Terry MJ; Oates AJ; Miyamoto Y; Chuu YH; Munakata M; Sekiya T
Oncogene; 2002 May; 21(23):3804-13. PubMed ID: 12032849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
